These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 17414883)

  • 21. 18F-FDG PET as a candidate for "qualified biomarker": functional assessment of treatment response in oncology.
    Larson SM; Schwartz LH
    J Nucl Med; 2006 Jun; 47(6):901-3. PubMed ID: 16741296
    [No Abstract]   [Full Text] [Related]  

  • 22. Role of 2-Deoxy-2-[18F]-fluoro-d-glucose-PET/Computed Tomography in Lymphoma.
    Tirumani SH; LaCasce AS; Jacene HA
    PET Clin; 2015 Apr; 10(2):207-25. PubMed ID: 25829087
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Positron emission tomography in gynecologic cancer.
    Yen TC; Lai CH
    Semin Nucl Med; 2006 Jan; 36(1):93-104. PubMed ID: 16356798
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Integrating PET and PET/CT into the risk-adapted therapy of lymphoma.
    Kasamon YL; Jones RJ; Wahl RL
    J Nucl Med; 2007 Jan; 48 Suppl 1():19S-27S. PubMed ID: 17204717
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas.
    Kumar R; Xiu Y; Potenta S; Mavi A; Zhuang H; Yu JQ; Dhurairaj T; Dadparvar S; Alavi A
    J Nucl Med; 2004 Nov; 45(11):1796-803. PubMed ID: 15534046
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Critical considerations on the predictive value of end-of-treatment FDG-PET in lymphoma.
    Adams HJA; Kwee TC
    Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):342-343. PubMed ID: 27783106
    [No Abstract]   [Full Text] [Related]  

  • 27. PET and PET/CT for response evaluation in lymphoma: current practice and developments.
    Brepoels L; Stroobants S; Verhoef G
    Leuk Lymphoma; 2007 Feb; 48(2):270-82. PubMed ID: 17325886
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Initial staging of lymphoma with positron emission tomography and computed tomography.
    Hicks RJ; Mac Manus MP; Seymour JF
    Semin Nucl Med; 2005 Jul; 35(3):165-75. PubMed ID: 16098290
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overview of early response assessment in lymphoma with FDG-PET.
    MacManus MP; Seymour JF; Hicks RJ
    Cancer Imaging; 2007; 7(1):10-8. PubMed ID: 17766210
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of FDG PET in the management of childhood lymphomas--case proven or is the jury still out?
    Shankar A; Fiumara F; Pinkerton R
    Eur J Cancer; 2008 Mar; 44(5):663-73. PubMed ID: 18313916
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Positron emission tomography in evaluating the response to treatment of brain tumors, lymphomas and breast cancer].
    Giannopoulou C; Fragaki C
    Hell J Nucl Med; 2006; 9(2):117-25. PubMed ID: 16894421
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reply to letter of Adams and Kwee: Critical considerations on the predictive value of end-of-treatment FDG/PET in lymphoma.
    Fallanca F; Alongi P; Incerti E; Gianolli L; Picchio M; Kayani I; Bomanji JB
    Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):344-345. PubMed ID: 27796542
    [No Abstract]   [Full Text] [Related]  

  • 33. PET/CT for therapy response assessment in lymphoma.
    Hutchings M; Barrington SF
    J Nucl Med; 2009 May; 50 Suppl 1():21S-30S. PubMed ID: 19380407
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [(18)F]FDG in childhood lymphoma: clinical utility and impact on management.
    Montravers F; McNamara D; Landman-Parker J; Grahek D; Kerrou K; Younsi N; Wioland M; Leverger G; Talbot JN
    Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1155-65. PubMed ID: 12192560
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Utility of fluorodeoxyglucose-PET imaging in the management of patients with Hodgkin's and non-Hodgkin's lymphomas.
    Kumar R; Maillard I; Schuster SJ; Alavi A
    Radiol Clin North Am; 2004 Nov; 42(6):1083-100. PubMed ID: 15488559
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PET and PET/CT in management of the lymphomas.
    Podoloff DA; Macapinlac HA
    Radiol Clin North Am; 2007 Jul; 45(4):689-96, vii. PubMed ID: 17706533
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Imaging: staging and evaluation of lymphoma using nuclear medicine.
    Divgi C
    Semin Oncol; 2005 Feb; 32(1 Suppl 1):S11-8. PubMed ID: 15786021
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The promise of immuno-PET in radioimmunotherapy.
    Verel I; Visser GW; van Dongen GA
    J Nucl Med; 2005 Jan; 46 Suppl 1():164S-71S. PubMed ID: 15653665
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The value of FDG-PET in the follow-up of differentiated thyroid cancer: a review of the literature.
    Stokkel MP; Duchateau CS; Dragoiescu C
    Q J Nucl Med Mol Imaging; 2006 Mar; 50(1):78-87. PubMed ID: 16557207
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Utility of brain FDG-PET in primary CNS lymphoma.
    Mohile NA; Deangelis LM; Abrey LE
    Clin Adv Hematol Oncol; 2008 Nov; 6(11):818-20, 840. PubMed ID: 19194366
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.